S-1/A: Palatin Technologies Eyes $50 Million Capital Raise Through Securities Offering

Palatin Technologies is seeking to raise capital through an offering of common stock, warrants, and pre-funded warrants, aiming to bolster working capital and fund development programs.

Summary

• Palatin Technologies is undertaking a best-efforts offering to sell up to 57,339,449 shares of common stock along with Series F and Series G common stock purchase warrants.
• The company is also offering pre-funded warrants as an alternative to common stock for certain purchasers.
• The assumed combined public offering price is $0.218 per share of common stock and accompanying warrants, based on the closing price on May 1, 2025.
• Series F warrants have an exercise price of 200% of the combined public offering price and expire five years from issuance, but can terminate earlier if Series G warrants are not fully exercised after FDA acceptance of an IND for an in-house obesity treatment.
• Series G warrants have an exercise price of 100% of the combined public offering price and expire either 24 months from issuance or after the FDA acceptance period.
• Exercising Series G warrants results in the issuance of Series H warrants, with an exercise price of 150% of the combined public offering price and expiring 24 months from the original issuance date.
• The offering is expected to close one trading day after the securities purchase agreement is entered into, with proceeds intended for working capital and general corporate purposes, including development work on bremelanotide combination products.
• The company is currently not in compliance with NYSE American listing standards and faces potential delisting if compliance is not regained.
• Recent developments include a sales agreement with A.G.P./Alliance Global Partners and a registered direct offering and concurrent private placement in February 2025.
• The company is also involved in litigation with H.C. Wainwright & Co., LLC.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively pursuing capital raising and has ongoing drug development programs, the financial instability, potential delisting, and litigation concerns weigh negatively on the overall outlook.

Positives

• The offering could provide significant working capital for Palatin Technologies.
• The company is actively engaged in discussions with potential partners and licensees that have the financial and operational resources to progress our products for ocular conditions through development, approval and commercialization.
• The company has multiple ongoing drug development programs.

Negatives

• The company is currently not in compliance with NYSE American listing standards and faces potential delisting.
• The company has a history of substantial net losses and may never achieve or maintain profitability.
• The company is involved in litigation with H.C. Wainwright & Co., LLC.
• The offering is a 'best efforts' offering, meaning there is no guarantee that all or any of the securities will be sold.

Risks

• The company has a history of substantial net losses and may never achieve or maintain profitability.
• The company needs additional funding, which may not be available on acceptable terms, if at all.
• The company is currently not in compliance with the continued listing standards of the NYSE American, and delisting could have significant adverse consequences.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution.
• There is no public market for the Common Warrants or Pre-Funded Warrants.
• The company may not receive any additional funds upon the exercise of the Common Warrants or Pre-Funded Warrants.
• The company may sell Common Stock or preferred stock in the future, stockholders may experience immediate dilution and, as a result, our stock price may decline.

Future Outlook

The company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for development work on its combination of bremelanotide and tirzepatide, a GLP-1 agonist.

Industry Context

The announcement reflects a common strategy among biopharmaceutical companies to raise capital for ongoing research and development, especially for companies with promising drug candidates but limited current revenue streams. The focus on melanocortin receptor system modulation places Palatin in a competitive landscape with other companies targeting similar pathways for various indications.

Comparison to Industry Standards

• Palatin's approach to drug development, particularly the focus on melanocortin receptor modulation, aligns with industry trends in targeted therapeutics.
• Comparable companies in the biopharmaceutical sector, such as Rhythm Pharmaceuticals (focused on melanocortin-4 receptor agonists for rare genetic diseases of obesity) and Zealand Pharma (developing peptide therapeutics), provide benchmarks for clinical development and commercialization strategies.
• The company's decision to out-license Vyleesi to Cosette Pharmaceuticals is a common strategy in the industry to leverage the commercial expertise of larger pharmaceutical companies.
• The company's current financial situation is not unique, as many small cap biopharma companies struggle to maintain listing compliance.

Legal Proceedings

• The company is involved in litigation with H.C. Wainwright & Co., LLC.

Stakeholder Impact

• Shareholders face potential dilution from the offering and the risk of delisting.
• Employees face uncertainty due to the company's financial instability.
• Customers may be impacted by the company's ability to continue developing and commercializing its products.
• Suppliers and creditors face the risk of non-payment due to the company's financial situation.

Next Steps

• The company will proceed with the best-efforts offering of common stock, warrants, and pre-funded warrants.
• The company will continue to develop its bremelanotide combination products and other drug candidates.
• The company will appeal the NYSE Regulations decision and attend a hearing on June 12, 2025.
• The company will continue to defend against the lawsuit filed by H.C. Wainwright & Co., LLC.

Key Dates

Keywords

Palatin Technologies, common stock, warrants, pre-funded warrants, securities offering, capital raise, NYSE American, bremelanotide, tirzepatide, clinical trials, FDA, listing compliance, A.G.P./Alliance Global Partners, Laidlaw & Company, H.C. Wainwright & Co.